On the recordSeptember 18, 2014
A combination of barriers, including, of course, the high cost of drug development and the small profit margins have helped to drive companies out of the anti-infectious space.
Source
congress.gov“A combination of barriers, including, of course, the high cost of drug development and the small profit margins have helped to drive companies out of the anti-infectious space.”
Barton discusses challenges in antibiotic drug development.
Share
More from Joe Barton
It is always good to have hearings like this to try to, through bipartisan basis, get facts on the table.
I thank the gentlewoman from Michigan for her kind words. I appreciate the nice gift I got yesterday from her and her husband, his new book, ``The Dean.'' I look forward to reading it over Christmas. Mr. Speaker, I yield 1 minute to the…
Other voices in this conversation